Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. (EIDX): 2 pipeline candidates · ~16 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.2 months
D/E 0.31 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for Eidos Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$147.3M
Quarterly Burn
$27.6M
Runway
16.2 mo
Revenue
$127K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| acoramidis | Phase 3 |
| ag10 | Preclinical |
Frequently asked questions
How many drug candidates are in Eidos Therapeutics, Inc.'s pipeline?
Eidos Therapeutics, Inc. (EIDX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Eidos Therapeutics, Inc.'s lead drug candidate?
Eidos Therapeutics, Inc.'s most advanced tracked candidate is acoramidis (Phase 3) for Amyloidosis.
What is Eidos Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Eidos Therapeutics, Inc. has approximately 16.2 months of cash runway.
Who is the CEO of Eidos Therapeutics, Inc.?
Neil Kumar is the chief executive officer of Eidos Therapeutics, Inc. (EIDX).
Get the full picture on Eidos Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.